Huntington’s Disease Research Reagents

Huntingtin (HTT/mHTT) — Polyglutamine-expanded mHTT aggregates into intranuclear inclusions and disrupts multiple cellular pathways. Anti-huntingtin antibodies (including polyQ-specific clones) enable mHTT quantification in CSF, aggregate detection by IHC, and HTT-lowering drug efficacy measurement.
→ Browse huntingtin antibodies & proteins

BDNF — Wild-type HTT promotes BDNF transcription and axonal transport; mHTT disrupts both, contributing to striatal neuron vulnerability. Anti-BDNF antibodies support neurotrophic signaling studies and neuroprotective therapy research.
→ Browse BDNF antibodies & proteins

NfL (Neurofilament Light Chain) — Plasma NfL is a validated biomarker correlating with HD disease stage and progression rate. Anti-NfL antibodies support longitudinal monitoring and clinical trial pharmacodynamic endpoints.

1. Tabrizi SJ, et al. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol. 2020;16(10):529-546. DOI

2. Byrne LM, et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease. Neurology. 2017;89(22):2309-2317. DOI

3. Tabrizi SJ, et al. Targeting huntingtin expression in patients with Huntington’s disease. N Engl J Med. 2019;380(24):2307-2316. DOI

4. Bates GP, et al. Huntington disease. Nat Rev Dis Primers. 2015;1:15005. DOI